Quick Answer
Tenaya Therapeutics, Inc. reported Operating Income of -$93.33 million for fiscal year 2025.
Tenaya Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$93.33M | +19.5% |
| 2024 | -$115.95M | +11.6% |
| 2023 | -$131.19M | -4.4% |
| 2022 | -$125.62M | -72.5% |
| 2021 | -$72.81M | -87.1% |
| 2020 | -$38.91M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$20.94M | +21.6% | +13.1% |
| June 30, 2025 | -$24.08M | +21.9% | +12.5% |
| March 31, 2025 | -$27.54M | +18.4% | -3.1% |
| September 30, 2024 | -$26.71M | +13.6% | +13.3% |
| June 30, 2024 | -$30.82M | +12.2% | +8.7% |
| March 31, 2024 | -$33.76M | -0.1% | -9.2% |
| September 30, 2023 | -$30.92M | +1.2% | +11.9% |
| June 30, 2023 | -$35.10M | -22.7% | -4.1% |
- Tenaya Therapeutics, Inc. showed an increase of +19.5% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Tenaya Therapeutics, Inc.’s operating income has declined by 139.9% (from -$38.91 million to -$93.33 million).
- The most recent figure is from Tenaya Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: